Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD4 T cell–mediated cardiac allograft rejection requires donor but not host MHC class II
Biagio A. Pietra, … , Mona Rizeq, Ronald G. Gill
Biagio A. Pietra, … , Mona Rizeq, Ronald G. Gill
Published October 15, 2000
Citation Information: J Clin Invest. 2000;106(8):1003-1010. https://doi.org/10.1172/JCI10467.
View: Text | PDF
Article

CD4 T cell–mediated cardiac allograft rejection requires donor but not host MHC class II

  • Text
  • PDF
Abstract

Numerous studies indicate that CD4 T cells are required for acute cardiac allograft rejection. However, the precise role for CD4 T cells in this response has remained ambiguous owing to the multipotential properties of this T-cell subpopulation. In the current study, we demonstrate the capacity of CD4 T cells to serve as direct effector cells of cardiac allograft rejection. We show that CD4 T cells are both necessary and sufficient for acute graft rejection, as indicated by adoptive transfer experiments in immune-deficient SCID and rag1–/– recipients. We have analyzed the contribution of direct (donor MHC class II restricted) and indirect (host MHC class II restricted) antigen recognition in CD4-mediated rejection. Acute CD4 T cell–mediated rejection required MHC class II expression by the allograft, indicating the importance of direct graft recognition. In contrast, reciprocal experiments indicate that CD4 T cells can acutely reject allogeneic cardiac allografts established in rag1–/– hosts that were also MHC class II deficient. This latter result indicates that indirect presentation of donor antigens by host MHC class II is not required for acute CD4-mediated rejection. Taken together, these results indicate that CD4 T cells can serve as effector cells for primary acute cardiac allograft rejection, predominantly via direct donor antigen recognition and independent of indirect reactivity.

Authors

Biagio A. Pietra, Alex Wiseman, Amy Bolwerk, Mona Rizeq, Ronald G. Gill

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
CD4 T cells are necessary for cardiac allograft rejection. (a) C57BL/6 c...
CD4 T cells are necessary for cardiac allograft rejection. (a) C57BL/6 cardiac allografts are rejected in immune competent BALB/c recipient (n = 10, mean = 8.3 ± 1.6 days), whereas mice treated with 10 mg/kg of anti-CD4 antibody (GK-1.5) do not reject C57BL/6 hearts (n = 4; >60 days × 4). (b) C57BL/6 cardiac allografts are not rejected in unreconstituted C.B-17scid (SCID) mice (n = 12; >60 days × 12). C57BL/6 cardiac allografts are rejected in SCID mice reconstituted with LN cells from immune competent BALB/c mice (n = 7; mean = 12.4 ± 4.5 days), whereas BALB/c cell donors treated with 10 mg/kg of anti-CD4 antibody (GK-1.5) before transfer do not reject C57BL/6 hearts (n = 4; >60 days × 4).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts